- Company
- Samsung Biologics signs 2 CMO contracts with Pfizer
- by Chon, Seung-Hyun Jul 5, 2023 05:44am
- Samsung Biologics signed two contract manufacturing organization agreements with Pfizer. The contracts, including the largest single contract ever made that is valued at KRW 922.7 billion (approximately USD 818 million), have been successfully concluded, totaling the amount to KRW 1.2 trillion (approximately USD 1.06 billion). On the 4th
- Company
- Samsung Bioepis launches Humira biosimilar in the US
- by Lee, Seok-Jun Jul 4, 2023 05:37am
- On July 3rd, Samsung Bioepis announced that it had released its Humira biosimilar ‘Hadlima (project name: SB5, ingredient: adalimumab) in the US through its partner Organon. Hadlima is a treatment for autoimmune diseases including rheumato
- Company
- Celltrion seeks approval for Stelara biosimilar in the US
- by Kim, Jin-Gu Jul 4, 2023 05:37am
- Celltrion announced on the 3rd that it has submitted an application for the approval of its Stelara (ustekinumab) biosimilar to the U.S. Food and Drug Administration (FDA). Its indications are the same as its original - plaque psoriasis, pediatric plaque psoriasis, psoriatic arthritis, pediatric psoriatic arthritis, Crohn's disease, and u
- Company
- Discussion on whether Vabysmo benefit is possible
- by Eo, Yun-Ho Jul 4, 2023 05:37am
- Attention is focusing on whether Vabysmo, a macular degeneration treatment, will be able to be listed on the insurance benefit list. According to related industries, it is expected that Vabysmo, a Bispecific antibody treatment in Roche Korea, will be presented to the Drug Benefit Evaluation Committee this month (July). This drug passed the Dr
- Opinion
- [Reporter’s View] Gvn't policies hinder KOR pharma growth
- by Lee, Tak-Sun Jul 4, 2023 05:37am
- It seems that the pro-business policy the new administration has been implementing to promote Korea’s industries is not benefiting the domestic pharmaceutical companies at all. Rather, the companies have expressed their regrets on how the authorities have been implementing policies that hinder their corporate activities, such as those that
- Company
- Forxiga expands its benefit through heart failure
- by Jung, Sae-Im Jul 4, 2023 05:36am
- Domestic and foreign cardiac societies recommend SGLT-2 for preserving exudation rates Forxiga, a blockbuster treatment with an annual prescription of 90 billion won, has expanded its scope to the entire heart failure. AstraZeneca Korea held a press conference at The Plaza Hotel in Jung-gu, Seoul on the 3rd to commemorate the expansion of chron
- Policy
- Mounjaro, a weight loss effect for DM pts, has been approved
- by Lee, Hye-Kyung Jul 3, 2023 05:47am
- Eli Lilly's 'Mounjaro PFS', known overseas as a game changer for obesity treatment, has been approved in Korea. In Korea, it has been approved as a treatment for diabetes. Mounjaro is a synthetic peptide with a mechanism that can selectively bind to both the GIP and GLP-1 receptors for the first time in Korea. The Ministry of Food and Dru
- Company
- Lagevrio was voluntarily withdrawn from Europe
- by Kim, Jin-Gu Jul 3, 2023 05:47am
- Merck has voluntarily withdrawn its European approval application for Lagevrio, an oral COVID-19 treatment. The pharmaceutical industry is paying close attention to whether the global supply of this drug will continue. Celltrion and Hanmi Pharmaceutical, which had already decided to produce and supply Lagevrio generics to developing countrie
- Company
- Leclaza and Tagrisso compete for reimb in the first line
- by Jung, Sae-Im Jul 3, 2023 05:47am
- Yuhan Corp’s EGFR-targeted anticancer drug ‘Leclaza (lasertinib)’ has been approved as a first-line treatment in Korea and is competing for reimbursement with its competitor ‘Tagrisso (osimertinib).’ As reimbursement review for Tagrisso’s first-line indication is already in progress, Yuhan is also expected to hasten its steps to re
- Policy
- Drug price negotiations such as Roche Evrysdi begin
- by Lee, Tak-Sun Jul 3, 2023 05:47am
- Roche's 5q spinal muscular dystrophy treatment Evrysdi Dry Syrup began negotiations with the NHIS as soon as it passed the Drug Benefit Evaluation Committee of the HIRA. Ace Pharma and H&O Pharm's multiple myeloma treatments Megval Inj. and Melpspal Inj. have also entered negotiations. The NHIS added oEvrysdi Dry Syrup 0.75 mg/mL, Melpspal In
